Innovent Biologics, Inc. (HKEX: 01801), a China-based biopharmaceutical company, announced on Monday that it has named Dr Nageatte Ibrahim as its new oncology CMO.

In the new role, Dr Ibrahim is to provide the strategy, execution and leadership for the Oncology Global Clinical Development program.

Dr Ibrahim has more than 11 years of oncology industry drug development experience at Merck and GSK. She also has nine years of faculty appointment, which includes an Instructor of Medicine at Harvard Medical School and attending physician at Dana-Farber Cancer Institute and later an adjunct assistant professor at Perlman School of Medicine/Abramson Cancer Center. She has worked as the vice president, Global Clinical Development, Oncology at Merck. Dr Ibrahim has also worked as the scientific advisor for the Melanoma Research.

Dr Michael Yu, Innovent founder, chairman and CEO, said, 'We are very excited to welcome Dr Nageatte Ibrahim onboard as our Oncology CMO in Global Clinical Development. Dr Ibrahim has extensive experience in global clinical development in oncology along with excellent leadership skills. We believe that with Dr Ibrahim joining Innovent, her talent and innovation will further enhance our clinical development capabilities in oncology, solidify our efforts in building a global clinical development platform and an international clinical team, develop a more innovative and cutting-edge pipeline with global First-in-Class and Best-in Class agents, and accelerate the innovation pace globally. Dr Nageatte Ibrahim will bring new momentum to reach Innovent's goal 'to be one of the world's leading biopharmaceutical companies.'